Press Releases PharmaEngine, Inc.

Equities

4162

TW0004162003

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
93.7 ^TWD	-1.68%		+6.48%	-11.18%

Apr. 24	PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors	CI
Mar. 18	PharmaEngine, Inc. Announces ONIVYDE Obtains TFDA Approval for New Regimen in First-Line Treatment of Metastatic PDAC	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PharmaEngine : Phase III RESILIENT trial evaluating Onivyde in second-line monotherapy for small cell lung cancer did not meet its primary endpoint	22-08-03	PU
PharmaEngine : to attend 1H22 financial status investor conference hosted by Cathay Securities	22-07-26	PU
PharmaEngine : Announcement on the record date for the capital increase of Employee Restricted Shares and related matters	22-07-26	PU
PharmaEngine : Announcement of the resolution by the company’s board of directors for the ex-dividend record date of cash dividends	22-07-26	PU
PharmaEngine : announces the board resolutions on approving the Second Quarter of 2022 consolidated financial report	22-07-26	PU
PharmaEngine : Announcement of the new chairperson of The Company	22-05-27	PU
PharmaEngine : The Company announced the new-elected members of the Audit Committee	22-05-27	PU
PharmaEngine : The Company announced the new-elected members of the Compensation Committee	22-05-27	PU
PharmaEngine : Important resolutions of the Company's 2022 Annual Shareholders' Meeting	22-05-27	PU
PharmaEngine : Announcement of the 2022 shareholders' meeting resolution of new-elected 9 directors (including 3 independent directors)	22-05-27	PU
PharmaEngine : to attend Cathay Securities Investor Conference hosted by Cathay Securities	22-04-28	PU
PharmaEngine : announces the board resolutions on approving the First Quarter of 2022 consolidated financial report.	22-04-28	PU
PharmaEngine : Clarification of media reporting	22-04-17	PU
PharmaEngine : announced that the China NMPA has granted approval for ONIVYDE Regimen for the Treatment of Metastatic Pancreatic Cancer	22-04-15	PU
PharmaEngine : to attend Yuanta Securities Investor Conference hosted by Yuanta Securities	22-03-08	PU
PharmaEngine : Announcement that the Company's Board of Directors resolved to issue restricted stock awards (RSA)	22-03-08	PU
PharmaEngine : The Company's Board of Directors resolved to convene the 2022 Annual General Shareholders' Meeting (Additional cause for convening the meeting)	22-03-08	PU
PharmaEngine : announces the board resolutions on approving the Full Year of 2021 consolidated financial report.	22-03-08	PU
PharmaEngine : Correction to December 2021 Consolidated Revenue and Full Year 2021 Accumulated Revenue Announcement	22-03-08	PU
PharmaEngine : Announcement of cancellation of the Company treasury shares and change of paid-in capital registration	22-03-01	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases PharmaEngine, Inc.

Equities

4162

TW0004162003

Press Releases

Filters